A client receiving cetuximab develops a new mild acneiform rash on the face and upper chest without blisters, skin sloughing, fever, or drainage. Which action should the nurse take?
1Tell the client the rash confirms cancer progression and request a different anticancer regimen.
2Apply benzoyl peroxide without an order and continue treatment without assessing the rash.
3Assess and report the rash, reinforce sun protection, and follow the prescribed skin-care plan.✓ Correct answer
4Stop cetuximab permanently before the provider grades the dermatologic reaction.
Explanation
Cetuximab can cause acneiform rash and other dermatologic toxicities. The nurse should assess and document the rash, monitor for infection or severe mucocutaneous findings, notify the treatment team, reinforce limited sun exposure, and implement the prescribed skin-care plan. Dose interruption, reduction, or permanent discontinuation depends on severity. A mild rash does not by itself prove cancer progression or require permanent discontinuation, and unreviewed acne products can worsen irritation.
Clinical reasoning EGFR inhibition disrupts normal skin and follicular signaling, producing acneiform lesions, dryness, fissures, and infection risk. Blisters, erosions, skin sloughing, or systemic findings require urgent escalation.
Decision rule Grade and report cetuximab skin toxicity, protect the skin from sun exposure, use the ordered treatment plan, and change the anticancer dose according to severity rather than stopping it independently.
Scenario 55-year-old male on cetuximab for metastatic colorectal cancer; develops papulopustular rash on face/chest at week 2.
Cetuximab dermatologic toxicity — EGFR-inhibitor skin effects that include acneiform rash, dryness, fissures, nail-fold inflammation, and infectious complications.
Acneiform rash — A follicular papulopustular eruption associated with EGFR inhibition that requires severity assessment and supportive skin care.
Hypomagnesemia from EGFR — Wasting nephropathy from EGFR blockade; check Mg routinely.